Recent Updates
Recently added Catalysts
BIVI Negative Sentiment Score: 20/100

BioVie Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights – BIVI

Key Takeaway: BioVie Inc. is facing a class action securities fraud lawsuit filed by Levi & Korsinsky, which claims that the company mismanaged its Phase 3 clinical trial. The lawsuit alleges that BioVie failed to provide adequate oversight and that the COVID-19 pandemic further hindered its efforts. As a result of these issues, the Phase 3 trial data may be unreliable, and investor statements about the company's operations were misleading. Investors affected by these events are encouraged to contact Levi & Korsinsky before March 19, 2024, for potential legal recourse.

Market Sentiment Analysis

CONCERNS & RISKS

  • Allegations of securities fraud impacting investor confidence and financial stability.
  • Concerns about lack of oversight during Phase 3 clinical trials.
  • COVID-19's negative effects on the company's operational capabilities.
  • Potential failure of the clinical trial to meet primary endpoints due to exclusions.

Full Press Release Details

NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioVie investors who were adversely affected by alleged securities fraud between August 5, 2021 and November 29, 2023. Follow the link below to get more information and be contacted by a member of our team:
BIVI investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) BioVie was not conducting proper oversight of its Phase 3 clinical trial; (2) the COVID-19 pandemic significantly and negatively impacted the Company's ability to adequately conduct proper oversight of the Phase 3 clinical trial; (3) due to lack of proper oversight and reliance on contract research organizations, the data from defendants' Phase 3 clinical trial faced a greater risk of being unreliable and that the majority of patients would have to be excluded from the clinical trial; (4) as a result of the significant exclusions from the trial results, the Phase 3 clinical trial would fail to meet its primary endpoints; and (5) statements about BioVie's business, operations, prospects, and compliance with current good clinical practices were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
WHAT'S NEXT? If you suffered a loss in BioVie during the relevant time frame, you have until March 19, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the BioVie Inc. class action lawsuit about?

The lawsuit addresses alleged securities fraud affecting BioVie investors from August 5, 2021, to November 29, 2023.

What is the deadline to join the BioVie lawsuit?

Investors must request to be a lead plaintiff by March 19, 2024.

Is there a cost to participate in the BioVie class action?

There are no out-of-pocket costs to join the class action for eligible members.

Who can investors contact for more information?

Investors can contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or call (212) 363-7500.

Why choose Levi & Korsinsky for the lawsuit?

Levi & Korsinsky has a proven track record in securities litigation, securing significant recoveries for shareholders.

Last updated: Feb 22, 2024